Sorry, you need to enable JavaScript to visit this website.
Skip to main content

VELTASSA is the only K+ binder with a sodium-free exchange1,2

Sodium may cause issues for your patients who cannot tolerate an increase in sodium load.3

Systolic and diastolic blood pressure during 52 weeks of treatment with VELTASSA3*
Group Baseline Mean (mmHg) Week 4 Mean change from baseline (mmHg) Week 8 Mean change from baseline (mmHg) Week 52 Mean change from baseline (mmHg)
Mild HK (>5.0 to 5.5 mEq/L) 153.5/83.6 –11.2/–6.8 –14.2/–7.3 –15.7/–8.0
Moderate–severe HK (>5.5 to <6.0 mEq/L) 153.8/81.9 –8.0/–5.8 –7.9/–4.7 –17.1/–9.2

*AMETHYST-DN 52-week study (N=304).

No edema warning

The prescribing information for VELTASSA does not include a warning about edema.

Calcium and phosphate levels of VELTASSA patients

Next
SEE MORE

INDICATION

VELTASSA is indicated for the treatment of hyperkalemia in adults and pediatric patients ages 12 years and older.

Limitation of Use: VELTASSA should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action.

top

INDICATION & Important Safety Information

Important Safety Information

VELTASSA is indicated for the treatment of hyperkalemia.

Limitation of Use: VELTASSA should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action.

CONTRAINDICATIONS

VELTASSA is contraindicated in patients with a history of a hypersensitivity reaction to VELTASSA or any of its components.

INDICATION

VELTASSA is indicated for the treatment of hyperkalemia in adults and pediatric patients ages 12 years and older.

Limitation of Use: VELTASSA should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

VELTASSA is contraindicated in patients with a history of a hypersensitivity reaction to VELTASSA or any of its components.

WARNINGS AND PRECAUTIONS

Worsening of Gastrointestinal Motility: Avoid use of VELTASSA in patients with severe constipation, bowel obstruction or impaction, including abnormal post-operative bowel motility disorders, because VELTASSA may be ineffective and may worsen gastrointestinal conditions. Patients with a history of bowel obstruction or major gastrointestinal surgery, severe gastrointestinal disorders, or swallowing disorders were not included in clinical studies.

Hypomagnesemia: VELTASSA binds to magnesium in the colon, which can lead to hypomagnesemia. In clinical studies, hypomagnesemia was reported as an adverse reaction in 5.3% of adult patients treated with VELTASSA. Approximately 9% of adult patients in clinical trials developed hypomagnesemia with a serum magnesium value < 1.4 mg/dL. Monitor serum magnesium. Consider magnesium supplementation in patients who develop low serum magnesium levels.

MOST COMMON ADVERSE REACTIONS

The most common adverse reactions (incidence ≥  2%) in adult patients treated with VELTASSA were constipation (7.2%), hypomagnesemia (5.3%), diarrhea (4.8%), nausea (2.3%), abdominal discomfort (2.0%) and flatulence (2.0%). Mild to moderate hypersensitivity reactions were reported in 0.3% of patients treated with VELTASSA and included edema of the lips.The safety profile of VELTASSA in a study of 14 pediatric patients ages 12 to 17 years was generally similar to that observed in adult patients.

  1. References:
  2. Kayexalate (sodium polystyrene sulfonate) [product information]. Bridgewater, NJ: Sanofi Aventis US LLC; 2017.
  3. Lokelma® (sodium zirconium cyclosilicate) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2021.
  4. Bakris GL, Pitt B, Weir MR, et al; for AMETHYST-DN Investigators. Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial. JAMA. 2015;314(2):151–161. doi:10.1001/jama.2015.7446